The complexity and diversity of cell and gene therapies and treatments still restrains the industry’s ability to identify and deliver the proper treatment and a positive patient experience. In 2023, I expect we will see a considerable increase in critical data gathering and machine learning analysis that will lead to substantive improvements. This use of…
Be The Match BioTherapies expands fully characterized cord blood unit offerings
Be The Match BioTherapies now offers cryopreserved cord blood units (CBU) as allogeneic cell therapy starting material. Potential applications of the CBUs include non-clinical, clinical and commercial use. The company’s registry has more than 266,000 fully-characterized CBUs from domestic cord blood banks. Be The Patch offers comprehensive characterization information about CBUs to identify therapy-matched units.…
More allogeneic therapy growth is likely in 2022: Here’s why
The market for allogeneic stem-cell transplants continues to grow. “We’re seeing an increased interest in allogeneic approaches and being able to have something readily available off the shelf,” said Joy Aho, senior product manager at Be The Match BioTherapies. The momentum of this growth is likely to continue for allogeneic therapies into 2022 as researchers…